Goal 2: Reduce Human Disease

Biology of Red Blood Cell Alloimmunization

What determines which individuals will develop RBC alloimmune responses resulting in clinically meaningful sequelae?


This question encompasses: 1) the generation of alloantibodies that limit the availability of compatible blood or cause hemolytic disease of the fetus or newborn (HDFN); 2) the distinction between clinically significant and insignificant alloantibody responses, especially within alloantibody specificities known to have a potential for hemolysis; 3) the biology of hyperhemolysis in patients with sickle cell disease (SCD); and 4) therapeutic interventions to prevent and/or mitigate RBC alloimmunization and its sequelae, including those involving the donor, the recipient, or the RBCs themselves.

Tags (Keywords associated with the idea)


44 net votes
58 up votes
14 down votes
Idea No. 457